HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Psychiatry17 papers

Nicotine use disorder

Last edited: 4/15/2026

Overview

Nicotine use disorder involves compulsive use of nicotine-containing products despite harmful consequences, characterized by symptoms like craving, tolerance, and withdrawal 1.

Diagnosis

  • Key Diagnostic Criteria: Presence of strong cravings, difficulty controlling use, tolerance development, withdrawal symptoms upon cessation 1.
  • Recommended Tests: Nicotine levels in blood or urine can confirm recent use but are not diagnostic alone 1.
  • Grading: Severity often assessed using validated scales like the Fagerström Test for Nicotine Dependence 1.

    • Management

  • First-Line Treatments: Behavioral counseling, particularly cognitive-behavioral therapy (CBT) 1.
  • Adjunctive Treatments:
    • - Pharmacotherapy: Nicotine replacement therapy (NRT) such as patches, gum, or lozenges; varenicline (Chantix) 1. - Bupropion: For those who do not respond to NRT or varenicline 1.

    Special Populations

  • Pregnancy: Avoid nicotine use; NRT may be considered under strict medical supervision to minimize fetal risk 1.
  • Pediatrics: Early intervention with behavioral support; pharmacological options are limited due to developmental concerns 1.
  • Elderly: Consider comorbidities; tailored behavioral interventions are crucial; cautious use of pharmacotherapy due to polypharmacy risks 1.
  • Comorbidities: Tailor cessation strategies considering coexisting conditions; integrated care approaches recommended 1.

    • Key Recommendations

  • Implement behavioral counseling as the cornerstone of treatment for nicotine use disorder (Evidence: Strong 1).
  • Consider pharmacotherapy with NRT or varenicline for enhanced cessation rates, especially in high-risk populations (Evidence: Moderate 1).
  • Tailor cessation strategies to individual patient needs, particularly in special populations like pregnant women and the elderly, balancing risks and benefits (Evidence: Expert opinion 1).

    • References

    1 Warburton DM. Nicotine issues. Psychopharmacology 1992. link

    Original source

    1. [1]
      Nicotine issues. — Warburton DM Psychopharmacology (1992)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG